Inventor · disambiguated record
Dimiter S. Dimitrov
Also filed as: DIMITROV DIMITER · DIMITROV DIMITER S · DIMITROV DIMITER STANCHEV
97 granted patents·42 pending applications·526 citations·filing 2002–2024
99Inventor score
Files withUS HEALTH43LENTIGEN TECH INC17DIMITROV DIMITER S13UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION9BIOMED VALLEY DISCOVERIES INC8
Top patents by PatentIndex Score
139 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0396US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0496US9790282B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsUS HEALTH·Filed 2014·Granted Oct 17, 2017·28 cites·29 claims
- 0596US9765142B2TEM8 antibodies and their use in treatment and detection of tumorsUS HEALTH·Filed 2014·Granted Sep 19, 2017·31 cites·49 claims
- 0695US10543263B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2018·Granted Jan 28, 2020·14 cites·12 claims
- 0795US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 0895US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 0994US10822379B1Molecules that bind to SARS-CoV-2UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION·Filed 2020·Granted Nov 3, 2020·70 cites·18 claims
- 1094US9416190B2Mesothelin antibodies and methods for eliciting potent antitumor activityUS HEALTH·Filed 2013·Granted Aug 16, 2016·31 cites·28 claims
- 1194US8313746B2Human monoclonal antibodies against hendra and nipah virusesDIMITROV DIMITER S·Filed 2011·Granted Nov 20, 2012·12 cites·14 claims
- 1293US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1393US10730941B2Antigen-binding proteins targeting CD56 and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Granted Aug 4, 2020·10 cites·36 claims
- 1493US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1593US8357783B2Human anti-mesothelin monoclonal antibodiesUS HEALTH·Filed 2009·Granted Jan 22, 2013·22 cites·23 claims
- 1693US7988971B2Human monoclonal antibodies against Hendra and Nipah virusesUS HEALTH·Filed 2005·Granted Aug 2, 2011·14 cites·16 claims
- 1792US10703816B2M971 chimeric antigen receptorsUS HEALTH·Filed 2018·Granted Jul 7, 2020·3 cites·18 claims
- 1892US9738726B2HER2-specific monoclonal antibodies and conjugates thereofUS HEALTH·Filed 2014·Granted Aug 22, 2017·12 cites·32 claims
- 1992US8911728B2High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteinsDIMITROV DIMITER S·Filed 2011·Granted Dec 16, 2014·16 cites·17 claims
- 2091US11702472B2Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jul 18, 2023·2 cites·31 claims
- 2191US9598492B2Human monoclonal antibodies specific for CD22THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES·Filed 2016·Granted Mar 21, 2017·8 cites·13 claims
- 2291US8871206B2Anti-human folate receptor beta antibodies and methods of usePURDUE RESEARCH FOUNDATION·Filed 2013·Granted Oct 28, 2014·15 cites·17 claims
- 2391US8580927B2Engineered antibody constant domain moleculesDIMITROV DIMITER S·Filed 2009·Granted Nov 12, 2013·13 cites·25 claims
- 2490US9279019B2Human monoclonal antibodies specific for CD22US HEALTH·Filed 2013·Granted Mar 8, 2016·10 cites·23 claims
- 2590US9206257B2Human monoclonal antibodies specific for glypican-3 and use thereofHO MITCHELL·Filed 2012·Granted Dec 8, 2015·8 cites·22 claims
- 2690US8591889B2Human monoclonal antibodies specific for CD22DIMITROV DIMITER S·Filed 2009·Granted Nov 26, 2013·12 cites·23 claims
- 2789US11066479B2Monoclonal antibodies targeting glypican-2 (GPC2) and use thereofUS HEALTH·Filed 2017·Granted Jul 20, 2021·4 cites·45 claims
- 2889US10548987B2Antibody-drug conjugates for targeting CD56-positive tumorsUS HEALTH·Filed 2016·Granted Feb 4, 2020·8 cites·16 claims
- 2988US10604582B2Anti-CD276 antibodies (B7H3)THE US SECRETARY DEPARTMENT OF HEALTH·Filed 2015·Granted Mar 31, 2020·4 cites·37 claims
- 3088US10072078B2M971 chimeric antigen receptorsUS HEALTH·Filed 2013·Granted Sep 11, 2018·7 cites·18 claims
- 3188US9181327B2Anti-HIV domain antibodies and method of making and using sameDIMITROV DIMITER S·Filed 2009·Granted Nov 10, 2015·9 cites·5 claims
- 3287US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 3387US10633441B2Mesothelin-targeted chimeric antigen receptors and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Apr 28, 2020·2 cites·41 claims
- 3486US10758614B2Combination therapies targeting tumor-associated stroma or tumor cells and topoisomeraseBIOMED VALLEY DISCOVERIES INC·Filed 2015·Granted Sep 1, 2020·3 cites·10 claims
- 3586US7803913B2Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display librariesUS HEALTH·Filed 2003·Granted Sep 28, 2010·11 cites·20 claims
- 3685US8071323B2Human monoclonal antibodies that bind human insulin like growth factors and their useDIMITROV DIMITER S·Filed 2007·Granted Dec 6, 2011·8 cites·52 claims
- 3785US2024084008A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 3885US2024084007A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 3984US8105598B2Human monoclonal antibodies that specifically bind IGF-IIDIMITROV DIMITER S·Filed 2010·Granted Jan 31, 2012·4 cites·33 claims
- 4083US12018077B2Methods of treatments using antigen-binding proteins targeting CD56MEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jun 25, 2024·1 cites·32 claims
- 4182US11878052B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2020·Granted Jan 23, 2024·1 cites·19 claims
- 4282US11078286B2Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their useUS HEALTH·Filed 2016·Granted Aug 3, 2021·2 cites·9 claims
- 4382US2025101088A1Monoclonal antibodies that specifically bind to matrilin 3 and their useUS HEALTH·Filed 2024·Application pending·0 cites
- 4481US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 4581US9527903B2Engineered antibody constant domain moleculesUS HEALTH·Filed 2013·Granted Dec 27, 2016·3 cites·11 claims
- 4680US7223844B2Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexesSCRIPPS RESEARCH INST·Filed 2002·Granted May 29, 2007·16 cites·27 claims
- 4780US2023312706A1Uses of mesothelin-targeted chimeric antigen receptorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2023·Application pending·0 cites
- 4880US2023331832A1Monoclonal antibodies that specifically bind to matrilin 3 and their useUS HEALTH·Filed 2023·Application pending·0 cites
- 4980US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 5079US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 139 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →